** Shares in Swiss-American eye care group Alcon ALCC.S drop 9.4% on revised 2025 outlook, impacted by U.S. tariffs, and Q1 results below estimates
** "This outlook incorporates a gross tariff impact of approximately $80 million, which is expected to pressure cost of net sales," the company said
** Alcon is more exposed than fields like cardiology, as ophthalmology procedures are often elective and can be delayed, said BTIG analyst Ryan Zimmerman ahead of results, commenting on U.S. impact, adding as well shares might be falling on recession fears
** The stock is on track for its worst day since March 2020, when it closed 10.6% lower
(Reporting by Anastasiia Kozlova)
((Anastasiia.Kozlova@thomsonreuters.com))